Loading...
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience, P Shah, M Ohtsu, A Van Cutsem, E Ajani, J Castro, H Mansoor, Was Chung, H Bodoky, G Shitara, K
Thuss-Patience, P
Shah, M
Ohtsu, A
Van Cutsem, E
Ajani, J
Castro, H
Mansoor, Was
Chung, H
Bodoky, G
Shitara, K
Citations
Altmetric:
Abstract
Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction).
Description
Date
2017-03-23
Publisher
Collections
Keywords
Type
Article
Citation
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. 2017, Lancet Oncol